Clinical trials: Lipids Metabolism
GM1 Gangliosidosis
Interviews and Video Capture in Patients With GM1 Gangliosidosis
GM1 gangliosidosis is a rare disease for which there is a limited understanding of disease progression and meaningful outcome measures.
- Trial name
- NCT04310163
- Testing
- Natural history
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- LYSOGENE
Hypertriglyceridemia
a Phase 1b/2a Study of JMT202 Injection in Participants With Hypertriglyceridemia
To evaluate the safety and tolerability of multiple subcutaneous injections of JMT202 injection in Chinese participants with hypertriglyceridemia
- Trial name
- phase Ib/Ⅱa st (NCT07140809)
- Testing
- JMT202 injection
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Shanghai JMT-Bio Inc.
Hypercholesterolemia
Single Dose Study of PF-06815345 in Healthy Subjects
The current study is the first clinical trial proposed with PF-06815345. It is designed to evaluate the safety, tolerability, and pharmacokinetics (PK) following administration of single oral doses of PF-06815345 to healthy adult…
- Trial name
- NCT02654899
- Testing
- PF-06815345
- Where
- Belgium
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Pfizer
Triglycerides, Weight Gain Trajectory
Effects of RDX-002 on Postprandial Triglycerides in Patients Discontinuing GLP-1 Agonists
The goal of this clinical trial is to learn if drug RDX-002 works to treat high levels of fat (known as triglycerides, or TGs) in the blood in adults. It will also learn about the safety of drug RDX-002.
- Conditions
- Triglycerides, Weight Gain Trajectory, Cholesterol, Elevated
- Trial name
- NCT06640972
- Testing
- RDX-002
- Where
- United States
- Volunteers
- 68 people
- Sponsor
- Response Pharmaceuticals
Hyperlipidemia or Mixed Dyslipidemia at High Risk for Cardiovascular Events
Study of Low-Density Lipoprotein Cholesterol (LDL-C) Reduction Using Evolocumab (AMG 145) in Japanese Patients With Advanced Cardiovascular Risk
The primary objective of the study was to evaluate the effect of 12 weeks of subcutaneous evolocumab administered every 2 weeks and once a month, compared with placebo, on percent change from baseline in LDL-C when used in…
- Trial name
- AMG145 (NCT01953328)
- Testing
- Atorvastatin, Evolocumab
- Where
- 54 sites in Japan
- Volunteers
- 409 people
- Sponsor
- Amgen
Dyslipidemia, Obesity
An International Study of Rimonabant in Dyslipidemia With AtheroGenic Risk In Abdominally Obese Patients
The purpose of this study is to assess the effect of rimonabant 20 mg on HDL (high density lipoprotein) cholesterol and on TG (triglycerides) plasma levels over a period of one year when prescribed with a hypocaloric diet (600…
- Trial name
- ADAGIO-lipids (NCT00239967)
- Testing
- Rimonabant (SR141716)
- Where
- 14 sites in United States, Australia and 12 more
- Volunteers
- 803 people
- Sponsor
- Sanofi
Hypertension and Dyslipidemia
A Combination Drug Including Fimasartan and Statins in Patients With Hypertension and Dyslipidemia
The primary objective of this study is to evaluate the effectiveness of a combination drug containing fimasartan and statins on the control of hypertension and dyslipidemia, and the secondary objective is to evaluate the drug…
- Trial name
- FIMASTAR (NCT04554953)
- Testing
- Combination drug containing fimasartan and statins
- Where
- South Korea
- Volunteers
- 10,877 people
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Fabry Disease
Evaluate the Safety and Efficacy of Fabagal® (Agalsidase Beta) in Patients With Fabry Disease
Evaluate the safety and efficacy of Fabagal® developed by ISU ABXIS Co., Ltd., which has similar efficacy to active comparator (Agalsidase beta).
- Trial name
- NCT06081062
- Testing
- Fabagal® (Agalsidase beta), Active comparator (Agalsidase beta)
- Where
- 3 sites in Philippines, South Korea
- Volunteers
- 24 people
- Sponsor
- ISU Abxis Co., Ltd.
Dyslipidemia
A Study of Evacetrapib in Participants With Abnormal Cholesterol
The main purpose of this study is to measure how much of the drug gets into the blood stream and how long it takes the body to get rid of it when given once a day for 12, 24, and 52 weeks to participants with abnormal amounts of…
- Trial name
- NCT02168803
- Testing
- Evacetrapib
- Where
- 3 sites in United States
- Volunteers
- 101 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Healthy Subjects、Lipid Metabolism
A Trial to Evaluate KPC000154 Tablets in Healthy Subjects
A Phase I Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of KPC000154 Tablets in Healthy Subjects
- Trial name
- KPC000154 (NCT06867406)
- Testing
- KPC000154 10mg Tablet Intervention, KPC000154 30mg Tablet Intervention, KPC000154 60mg Tablet Intervention
- Where
- China
- Volunteers
- 92 people, healthy volunteers welcome
- Sponsor
- Kunming Pharmaceuticals, Inc.
Hypercholesterolemia
LDL-Cholesterol Lowering Effect of KB2115 as Add on to Ezetimibe
Eprotirome (KB2115) is a liver selective thyroid hormone that can induce hyperthyroidism in the liver, while an euthyroid state is preserved in the extrahepatic tissue.
- Trial name
- NCT00677248
- Testing
- Eprotirome and ezetimibe
- Where
- Sweden
- Volunteers
- 120 people
- Sponsor
- Karo Bio AB
Heterozygous Familial Hypercholesterolemia
Exploratory Study of Plaque Regression
Despite the availability of several classes of very effective drugs available to treat heterozygous Familial Hypercholesterolemia (HeFH), there remains a large unmet medical need for new, effective and well tolerated therapies.
- Trial name
- EXPRESS (NCT01515241)
- Testing
- CER-001
- Where
- Canada
- Volunteers
- 10 people
- Sponsor
- Cerenis Therapeutics, SA
Essential Hypertension, Hyperlipidemia
Study to Investigate the Effect of Telmisartan/S-amlodipine on the Pharmacokinetic Properties of Atorvastatin.
The purpose of this study is to investigate the effect of telmisartan/s-amlodipine on the pharmacokinetic properties of atorvastatin.
- Trial name
- CKD-345 (NCT01842256)
- Testing
- Telmisartan 80mg, S-amlodipine 5mg and Atorvastatin 40mg, atorvastatin 40mg
- Where
- South Korea
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Chong Kun Dang Pharmaceutical
Dyslipidemia
A Study to Evaluate MK1903 in Patients With Dyslipidemia (MK1903-004)
This study will evaluate the lipid-modifying effect and tolerability of MK1903 when compared to placebo in patients with dyslipidemia who are not on a statin or other lipid-modifying therapy.
- Trial name
- NCT00847197
- Testing
- MK1903
- Volunteers
- 191 people
- Sponsor
- Merck Sharp & Dohme LLC
Hyperlipidemias, Hypertension
Evaluating the Pharmacokinetic Interaction Between AD-2011 and AD-2012
The purpose of this study is to evaluate the Pharmacokinetic Interaction Between AD-2011 and AD-2012 in healthy male volunteers.
- Trial name
- NCT03586037
- Testing
- AD-2011 10/20 mg, AD-2012 80mg, AD-2011 10/20 mg + AD-2012 80mg
- Where
- South Korea
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Addpharma Inc.
Hyperlipidemia
A Study of Torcetrapib/Atorvastatin vs Atorvastatin Alone or Placebo in Patients With High Cholesterol
The Torcetrapib project was terminated on December 2, 2006 due to safety findings. A study to look at lipid levels in subjects taking the study drug, Atorvastatin alone or placebo.
- Trial name
- NCT00138762
- Testing
- torcetrapib/atorvastatin, atorvastatin
- Where
- 154 sites in United States, Belgium and 6 more
- Volunteers
- 3,800 people
- Sponsor
- Pfizer
Fabry Disease
Extension Study of PRX-102 for up to 60 Months
To evaluate the ongoing safety, tolerability, and efficacy parameters of PRX-102 in adult Fabry patients who have successfully completed treatment with PRX-102 in studies PB-102-F01 and PB-102-F02.
- Trial name
- NCT01981720
- Testing
- PRX-102 (pegunigalsidase alfa)
- Where
- 8 sites in United States, Paraguay and 2 more
- Volunteers
- 15 people
- Sponsor
- Protalix
Hypercholesterolemia, Familial Hypercholesterolemia
A Study of Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) in Adults With Heterozygous Familial Hypercholesterolemia (MK-0616-017/CORALreef HeFH)
The goal of this study is to evaluate the efficacy, safety, and tolerability of enlicitide decanoate in adult participants with heterozygous familial hypercholesterolemia.
- Trial name
- NCT05952869
- Testing
- Enlicitide Decanoate
- Where
- 59 sites in United States, Australia and 15 more
- Volunteers
- 303 people
- Sponsor
- Merck Sharp & Dohme LLC
Fabry Disease
A Study to Assess the Absorption, Metabolism and Excretion of Migalastat Hydrochloride (AT1001-014)
This study is designed to describe the metabolism of AT1001 (migalastat HCl) and the contribution of metabolism and urinary excretion to its overall elimination as part of the continuing assessment of the safety and effectiveness…
- Trial name
- NCT01730482
- Testing
- [14C] AT1001
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Amicus Therapeutics
Dyslipidemia, Coronary Heart Disease
Evaluate Safety and Efficacy of ABT-335 in Combination With Rosuvastatin Calcium in Subjects With Multiple Abnormal Lipid Levels in the Blood
The purpose of this study is to compare the safety and efficacy of fenofibric acid (ABT-335) + rosuvastatin calcium combination therapy with ABT-335 and rosuvastatin calcium monotherapy in subjects with multiple abnormal lipid…
- Conditions
- Dyslipidemia, Coronary Heart Disease, Mixed Dyslipidemia
- Trial name
- NCT00300482
- Testing
- ABT-335, Rosuvastatin Calcium
- Where
- United States
- Volunteers
- 1,445 people
- Sponsor
- Abbott
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.